Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer’s disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay

[1]  Zhi-yuan Yu,et al.  Elevated Plasma Oligomeric Amyloid β-42 Is Associated with Cognitive Impairments in Cerebral Small Vessel Disease , 2023, Biosensors.

[2]  Haiming Luo,et al.  Colorimetric and surface-enhanced Raman scattering dual-mode magnetic immunosensor for ultrasensitive detection of blood phosphorylated tau in Alzheimer's disease. , 2022, Biosensors & bioelectronics.

[3]  Xiaofei Zhao,et al.  Qualitative and quantitative detection of microcystin-LR based on SERS-FET dual-mode biosensor. , 2022, Biosensors & bioelectronics.

[4]  Ningtao Cheng,et al.  An intelligent serological SERS test toward early-stage hepatocellular carcinoma diagnosis through ultrasensitive nanobiosensing , 2022, Nano Research.

[5]  Sungbo Cho,et al.  Fluorescent Aptasensor and Colorimetric Aptablot for p-tau231 Detection: Toward Early Diagnosis of Alzheimer’s Disease , 2022, Biomedicines.

[6]  Haiming Luo,et al.  Nanozyme sensor array based on manganese dioxide for the distinction between multiple amyloid β peptides and their dynamic aggregation process. , 2021, Biosensors & bioelectronics.

[7]  Haiming Luo,et al.  Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay , 2021, Journal of Nanobiotechnology.

[8]  Zhihong Zhang,et al.  Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease , 2021, Journal of Innovative Optical Health Sciences.

[9]  D. Selkoe,et al.  An ultra‐sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[10]  Juan-Yu Yang,et al.  Single-walled carbon nanotube based SERS substrate with single molecule sensitivity , 2021, Nano Research.

[11]  Jiajie Liang,et al.  Application of the amplification-free SERS-based CRISPR/Cas12a platform in the identification of SARS-CoV-2 from clinical samples , 2021, Journal of Nanobiotechnology.

[12]  Zhihong Zhang,et al.  Dynamic Changes in the Levels of Amyloid-β42 Species in the Brain and Periphery of APP/PS1 Mice and Their Significance for Alzheimer’s Disease , 2021, Frontiers in Molecular Neuroscience.

[13]  Soo Hyeon Kim,et al.  Surface-Enhanced Raman Scattering-Based Dual-Flow Lateral Flow Assay Sensor for the Ultrasensitive Detection of the Thyroid-Stimulating Hormone. , 2021, Analytical chemistry.

[14]  Xuan-Hung Pham,et al.  Au–Ag assembled on silica nanoprobes for visual semiquantitative detection of prostate-specific antigen , 2021, Journal of Nanobiotechnology.

[15]  Zhenpeng Qin,et al.  Ultrasensitive and Highly Specific Lateral Flow Assays for Point-of-Care Diagnosis. , 2021, ACS nano.

[16]  K. Blennow,et al.  Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.

[17]  P. Verstreken,et al.  Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation , 2021, Acta Neuropathologica.

[18]  Tianxing Ji,et al.  Background-Free Chromatographic Detection of Sepsis Biomarker in Clinical Human Serum through Near-Infrared to Near-Infrared Upconversion Immunolabeling. , 2020, ACS nano.

[19]  Shengqi Wang,et al.  Rapid, Quantitative, High-Sensitive Detection of Escherichia coli O157:H7 by Gold-Shell Silica-Core Nanospheres-Based Surface-Enhanced Raman Scattering Lateral Flow Immunoassay , 2020, Frontiers in Microbiology.

[20]  G. Millhauser,et al.  Evidence for aggregation-independent, PrPC-mediated Aβ cellular internalization , 2020, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Y. Ozaki,et al.  In-situ fingerprinting phosphorylated proteins via surface-enhanced Raman spectroscopy: Single-site discrimination of Tau biomarkers in Alzheimer's disease. , 2020, Biosensors & bioelectronics.

[22]  Matthias Kohl,et al.  Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay , 2020, Journal of Nanobiotechnology.

[23]  Rich Hartman,et al.  Exosomes in Alzheimer’s Disease: Potential Role as Pathological Mediators, Biomarkers and Therapeutic Targets , 2020, Neurochemical Research.

[24]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[25]  R. Bateman,et al.  Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease , 2020, The Journal of experimental medicine.

[26]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[27]  K. Blennow,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[28]  Wei Feng,et al.  Near infrared lanthanide-doped nanoparticles for low interference lateral flow immunoassay test. , 2020, ACS applied materials & interfaces.

[29]  V. Zucolotto,et al.  Colorimetric Paper-Based Immunosensor for Simultaneous Determination of Fetuin B and Clusterin Towards Early Alzheimer's Diagnosis. , 2019, ACS nano.

[30]  Haiming Luo,et al.  Instrument-Free and Visual Detection of Salmonella Based on Magnetic Nanoparticles and an Antibody Probe Immunosensor , 2019, International journal of molecular sciences.

[31]  Lingxin Chen,et al.  Highly sensitive detection of prostate cancer specific PCA3 mimic DNA using SERS-based competitive lateral flow assay. , 2019, Nanoscale.

[32]  J. Jia,et al.  Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid , 2019, Alzheimer's & Dementia.

[33]  Zhijun Zhang,et al.  Platelet Amyloid-β Protein Precursor (AβPP) Ratio and Phosphorylated Tau as Promising Indicators for Early Alzheimer's Disease. , 2019, The journals of gerontology. Series A, Biological sciences and medical sciences.

[34]  M. Hong,et al.  Toward Flexible Surface‐Enhanced Raman Scattering (SERS) Sensors for Point‐of‐Care Diagnostics , 2019, Advanced science.

[35]  S. Wereley,et al.  Magnetic Focus Lateral Flow Sensor for Detection of Cervical Cancer Biomarkers. , 2019, Analytical chemistry.

[36]  Dan J Stein,et al.  Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[37]  J. Hardy,et al.  Alzheimer's disease , 2018, European journal of neurology.

[38]  R. Bateman,et al.  Stop Alzheimer’s before it starts , 2017, Nature.

[39]  J. Kneipp,et al.  Surface enhanced hyper Raman scattering (SEHRS) and its applications. , 2017, Chemical Society reviews.

[40]  Yvonne S. Eisele,et al.  Progression of Seed‐Induced Aβ Deposition within the Limbic Connectome , 2015, Brain pathology.

[41]  L. Walker,et al.  Transport of cargo from periphery to brain by circulating monocytes , 2015, Brain Research.

[42]  R. Petersen,et al.  Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study , 2015, Alzheimer's & Dementia.

[43]  J. Trojanowski,et al.  Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains , 2015, Acta Neuropathologica.

[44]  V. Lee,et al.  Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases , 2014, Nature Medicine.

[45]  G. Perry,et al.  Phosphorylation of tau protein at sites Ser396–404 is one of the earliest events in Alzheimer's disease and Down syndrome , 2014, Neuropathology and applied neurobiology.

[46]  M. Tolnay,et al.  Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies , 2014, Neuropharmacology.

[47]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[48]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[49]  Madhav Thambisetty,et al.  Blood-based biomarkers of Alzheimer's disease: challenging but feasible. , 2010, Biomarkers in medicine.

[50]  W. Chan,et al.  Synthesis and surface modification of highly monodispersed, spherical gold nanoparticles of 50-200 nm. , 2009, Journal of the American Chemical Society.

[51]  A. Lees,et al.  Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies , 2009, Journal of Neuroscience Methods.

[52]  W. Noble,et al.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. , 2009, Trends in molecular medicine.

[53]  I. Grundke‐Iqbal,et al.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. , 2002, The American journal of pathology.

[54]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[55]  K. Blennow,et al.  Blood-based biomarkers for Alzheimer’s disease: mapping the road to the clinic , 2018 .

[56]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[57]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[58]  E.E. Pissaloux,et al.  Image Processing , 1994, Proceedings. Second Euromicro Workshop on Parallel and Distributed Processing.